Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.

Teixeira VH, Pipinikas CP, Pennycuick A, Lee-Six H, Chandrasekharan D, Beane J, Morris TJ, Karpathakis A, Feber A, Breeze CE, Ntolios P, Hynds RE, Falzon M, Capitanio A, Carroll B, Durrenberger PF, Hardavella G, Brown JM, Lynch AG, Farmery H, Paul DS, Chambers RC, McGranahan N, Navani N, Thakrar RM, Swanton C, Beck S, George PJ, Spira A, Campbell PJ, Thirlwell C, Janes SM.

Nat Med. 2019 Mar;25(3):517-525. doi: 10.1038/s41591-018-0323-0. Epub 2019 Jan 21.

PMID:
30664780
2.

Lung function changes after chemoradiation therapy in patients with lung cancer treated by three usual platinum combinations.

Mihailidis V, Anevlavis S, Karpathiou G, Kouliatsis G, Tzouvelekis A, Zarogoulidis P, Ntolios P, Steiropoulos P, Bouros D, Froudarakis ME.

J Thorac Dis. 2018 Sep;10(9):5435-5442. doi: 10.21037/jtd.2018.08.139.

3.

Longitudinal outcomes of patientsĀ enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.

Ntolios P, Manoloudi E, Tzouvelekis A, Bouros E, Steiropoulos P, Anevlavis S, Bouros D, Froudarakis ME.

Clin Respir J. 2018 Jun;12(6):2084-2089. doi: 10.1111/crj.12777. Epub 2018 Mar 12.

PMID:
29412521
4.

Corrigendum: Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D.

Front Med (Lausanne). 2018 Jan 24;4:257. doi: 10.3389/fmed.2017.00257. eCollection 2017.

5.

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.

Tzouvelekis A, Karampitsakos T, Kontou M, Granitsas A, Malliou I, Anagnostopoulos A, Ntolios P, Tzilas V, Bouros E, Steiropoulos P, Chrysikos S, Dimakou K, Koulouris N, Bouros D.

Pulm Pharmacol Ther. 2018 Apr;49:61-66. doi: 10.1016/j.pupt.2018.01.006. Epub 2018 Jan 31.

PMID:
29366978
6.

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D.

Front Med (Lausanne). 2017 Nov 29;4:213. doi: 10.3389/fmed.2017.00213. eCollection 2017. Erratum in: Front Med (Lausanne). 2018 Jan 24;4:257.

7.

Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.

Tzouvelekis A, Ntolios P, Karampitsakos T, Tzilas V, Anevlavis S, Bouros E, Steiropoulos P, Koulouris N, Stratakos G, Froudarakis M, Bouros D.

Pulm Pharmacol Ther. 2017 Oct;46:48-53. doi: 10.1016/j.pupt.2017.08.011. Epub 2017 Aug 24.

PMID:
28843616
8.

Mean Platelet Volume as a Surrogate Marker for Platelet Activation in Patients With Idiopathic Pulmonary Fibrosis.

Ntolios P, Papanas N, Nena E, Boglou P, Koulelidis A, Tzouvelekis A, Xanthoudaki M, Tsigalou C, Froudarakis ME, Bouros D, Mikhailidis DP, Steiropoulos P.

Clin Appl Thromb Hemost. 2016 May;22(4):346-50. doi: 10.1177/1076029615618023. Epub 2015 Dec 9.

PMID:
26659450
9.

Unilateral pulmonary artery agenesis: a case series.

Steiropoulos P, Archontogeorgis K, Tzouvelekis A, Ntolios P, Chatzistefanou A, Bouros D.

Hippokratia. 2013 Jan;17(1):73-6.

10.

A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.

Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, Kolios G, Bouros D.

J Transl Med. 2013 Jul 15;11:171. doi: 10.1186/1479-5876-11-171.

11.

Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis.

Tzouvelekis A, Ntolios P, Karameris A, Vilaras G, Boglou P, Koulelidis A, Archontogeorgis K, Kaltsas K, Zacharis G, Sarikloglou E, Steiropoulos P, Mikroulis D, Koutsopoulos A, Froudarakis M, Bouros D.

Biomed Res Int. 2013;2013:654354. doi: 10.1155/2013/654354. Epub 2013 Jun 9.

12.

Stem cell treatment for chronic lung diseases.

Tzouvelekis A, Ntolios P, Bouros D.

Respiration. 2013;85(3):179-92. doi: 10.1159/000346525. Epub 2013 Jan 29. Review. Erratum in: Respiration. 2013;86(4):294.

13.

Mesenchymal stem cell therapy for lung diseases: oasis or mirage?

Ntolios P, Janes SM.

Respiration. 2013;85(4):279-80. doi: 10.1159/000346642. Epub 2013 Jan 24. No abstract available.

14.

Expression of hypoxia-inducible factor (HIF)-1a-vascular endothelial growth factor (VEGF)-inhibitory growth factor (ING)-4- axis in sarcoidosis patients.

Tzouvelekis A, Ntolios P, Karameris A, Koutsopoulos A, Boglou P, Koulelidis A, Archontogeorgis K, Zacharis G, Drakopanagiotakis F, Steiropoulos P, Anevlavis S, Polychronopoulos V, Mikroulis D, Bouros D.

BMC Res Notes. 2012 Nov 26;5:654. doi: 10.1186/1756-0500-5-654.

15.

Idiopathic pulmonary hemosiderosis in adults: a case report and review of the literature.

Tzouvelekis A, Ntolios P, Oikonomou A, Koutsopoulos A, Sivridis E, Zacharis G, Kaltsas K, Boglou P, Mikroulis D, Bouros D.

Case Rep Med. 2012;2012:267857. doi: 10.1155/2012/267857. Epub 2012 Jul 18.

16.

Into the matrix: targeting fibroblasts in pulmonary fibrosis.

Sivakumar P, Ntolios P, Jenkins G, Laurent G.

Curr Opin Pulm Med. 2012 Sep;18(5):462-9. doi: 10.1097/MCP.0b013e328356800f. Review.

PMID:
22847104
17.

Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis.

Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, Koulelidis A, Oikonomou A, Bouros D.

Pulm Med. 2012;2012:143637. doi: 10.1155/2012/143637. Epub 2012 May 10.

18.

Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.

Tzouvelekis A, Bouros E, Oikonomou A, Ntolios P, Zacharis G, Kolios G, Bouros D.

Pulm Med. 2011;2011:849035. doi: 10.1155/2011/849035. Epub 2011 Nov 1.

19.

Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.

Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Kolios G, Kakagia D, Paspaliaris V, Kotsianidis I, Froudarakis M, Bouros D.

J Transl Med. 2011 Oct 21;9:182. doi: 10.1186/1479-5876-9-182.

Supplemental Content

Loading ...
Support Center